Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective

Author(s): Javed Ahmad, Sohail Akhter*, Md. Rizwanullah, Mohammad Ahmed Khan, Lucie Pigeon, Richard T. Addo, Nigel H. Greig, Patrick Midoux, Chantal Pichon, Mohammad Amjad Kamal.

Journal Name: Current Alzheimer Research

Volume 14 , Issue 11 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer


Background: Alzheimer's disease (AD), a cognitive dysfunction/dementia state amongst the elders is characterized by irreversible neurodegeneration due to varied pathophysiology. Up till now, anti-AD drugs having different pharmacology have been developed and used in clinic. Yet, these medications are not curative and only lowering the AD associated symptoms. Improvement in treatment outcome required drug targeting across the blood-brain barrier (BBB) to the central nervous system (CNS) in optimal therapeutic concentration. Nanotechnology based diagnostic tools, drug carriers and theranostics offer highly sensitive molecular detection, effective drug targeting and their combination. Over the past decade, significant works have been done in this area and we have seen very remarkable outocome in AD therapy. Various nanoparticles from organic and inorganic nanomaterial category have successfully been investigated against AD.

Conclusion: This paper discussed the role of nanoparticles in early detection of AD, effective drug targeting to brain and theranostic (diagnosis and therapy) approaches in AD's management.

Keywords: Alzheimer's disease, blood brain barrier, diagnosis, theranostic, nanoparticles, nanomedicines.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1164 - 1181]
Pages: 18
DOI: 10.2174/1567205014666170508121031
Price: $58

Article Metrics

PDF: 36